Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01241162 · ClinicalTrials.gov registry record · Phase 1
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
A Phase 1 study of Neuroblastoma and Rhabdomyosarcoma, sponsored by University of Louisville.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT01241162 is a Phase 1 study of Neuroblastoma and Rhabdomyosarcoma that has completed, run by University of Louisville. The registered enrollment target is 19 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01241162, a Phase 1 study of Neuroblastoma and Rhabdomyosarcoma, has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
This treatment study for relapsed high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma involves an autologous cancer testis (CT) antigen specific dendritic cell (DC) vaccine preceded by decitabine as a demethylating chemotherapy.
Conditions Studied
Interventions
- BIOLOGICAL Autologous dendritic cell vaccine with adjuvant
Study Locations (1)
Kentucky
- University of Louisville, Kosair Charities Pediatric Clinical Research Unit - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-08 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01241162
The ClinicalTrials.gov registry entry for NCT01241162 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (92% lower). The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Autologous dendritic cell vaccine with adjuvant is the first listed.
NCT01241162 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT01241162 about?
NCT01241162 is a clinical study titled "Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma". This treatment study for relapsed high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma involves an autologous cancer testis (CT) antigen specific dendritic cell (DC) vaccine preceded by decitabine as a demethylating chemotherapy.
What is the current status of trial NCT01241162?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2010-08. Estimated completion is 2016-10.
What conditions does trial NCT01241162 study?
This clinical trial studies the following conditions: Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Ewing's Sarcoma, Osteogenic Sarcoma.
What interventions are being tested in trial NCT01241162?
The interventions under investigation include: Autologous dendritic cell vaccine with adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01241162?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01241162 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.